Evaluación de nuevas formulaciones de fármacos antihelmínticos para el tratamiento de la esquistosomiasis
Contenido principal del artículo
Resumen
Palabras clave:
Descargas
Detalles del artículo
Citas
AMSE.es [Internet]. España: Asociación de Médicos de Sanidad Exterior; 2011 [actualizado Abril 2013; acceso Junio 2016]. Disponible en: http://www.amse.es.
Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanism of action, resistance, and new derivatives of Schistosomiasis. Current Opinion in Infectious Diseases, (2008); 21: 659–667.
Gryseels B, Karja P, Clerinx J, Kestens L. Human schistosomiasis. Lancet, 2006: 368: 1106-18.
Hemen A, Kela SL, Istifanus WA. Chemotherapeutic Trials of Praziquantel and Ivermectin on victims of Urinary Schistosomiasis in Taraba North Senatorial District. Sci-Afric Journal of Scientific Issues, 2014; 2(4): 156-159.
Ismail M, Botros S, Metwally S, Farghally A, Tao LF, Day TA et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. The american Journal of Tropical Medicine and Hygiene, (1999); 60: 932-935.
Muro A, Pérez del Villar L, Velasco V, Pérez Arellano JL. Infecciones por trematodos. Medicine. 2010; 10(53): 3171-28.
Ribeiro de Souza AL, Andreani T, Nunes de Oliveira R, Princila Kiill C, Kolenyak dos Santos F, Marques Allegretti S et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. International Journal of Pharmaceutics, 2014; 463: 31-37.
Scalise ML, Arrúa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies. American Journal of Tropical Medicine and Hygiene, (2016). PMID: 27246447
Shoop WL, Ostlind DA, Rohrer SP, Mickle G, Haines HW, Michael BF et al. Avermectins and Milbemycins Against Fasciola hepatica: In Vivo Drug Efficacy and In Vitro Receptor Binding. International Journal for Parasitology, (1995); 25(8): 923-927.
Taman A, Samar EB, Nora ET, Amira EH, Manar A. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. Journal of Coastal Life Medicine, 2014; 2(10): 817-823.
Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang YS. Schistosomiasis. Current Protocols in Immunology, (2013); 19(1): 1-58. doi:10.1002/0471142735.im1901s103.
Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Transactions of the Royal Society of Tropical Medicine and Hygiene, (1991); 85(2): 232-4.
WHO.int [Internet]. Organización Mundial de la Salud [actualizado Enero 2016; citado Junio 2016]. Disponible en: http://www.who.int/mediacentre/factsheets/fs115/es/
Yepes E, Varela-M RE, López-Abán J, Rojas-Caraballo J, Muro A, Mollinedo F (2015). Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. PLoS Neglected Tropical Disease 9(7): e0003893. doi:10.1371/journal. pntd.0003893.
Yepes E, Varela-M RE, López-Abán J, Habib Dakir EL, Mollinedo F, Muro A. In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine. PLoS ONE, (2014): 9(10): e109431. doi:10.1371/journal.pone.0109431.